CalciMedica CSO buys 1,000 CALC shares at $1.85 – Form 4 filing
Rhea-AI Filing Summary
On 07/01/2025, CalciMedica, Inc. (ticker CALC) filed a Form 4 disclosing that its Chief Scientific Officer, Kenneth A. Stauderman, executed a single open-market purchase marked with transaction code “P.” The transaction, carried out through his spouse’s account, involved 1,000 shares of CalciMedica common stock at a price of $1.85 per share, for an aggregate cost of roughly $1,850. Following the purchase, Stauderman reports indirect beneficial ownership of the 1,000 newly acquired shares and direct ownership of 11,944 shares. No derivative transactions were reported, and the filing is made solely by one reporting person. The form does not indicate use of a Rule 10b5-1 plan.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insignificant insider buy—1,000 CALC shares at $1.85; signals limited confidence, immaterial to valuation.
The disclosed purchase is very small—about $1.9 k—relative to CalciMedica’s daily trading volume and market capitalization. While insider buying can be interpreted as a positive signal, the size here is too minor to materially influence investor sentiment or fundamentals. The transaction increases total insider ownership only fractionally (rough insider stake data not provided). With no accompanying sales, it neither strengthens nor weakens governance outlook. Accordingly, I view the filing as informational but not impactful for valuation or trading strategy.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $1.85 | $2K |
| holding | Common Stock | -- | -- | -- |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CalciMedica (CALC) report on 07/02/2025?
Was the transaction executed under a Rule 10b5-1 plan?
Did the Form 4 disclose any derivative security activity?
AI-generated analysis. How Rhea-AI works. Not financial advice.